» Articles » PMID: 26277114

Identification of Clinical Parameters Predictive of One-year Survival Using Two Geriatric Tools in Clinically Fit Older Patients with Hematological Malignancies: Major Impact of Cognition

Overview
Journal J Geriatr Oncol
Publisher Elsevier
Specialty Geriatrics
Date 2015 Aug 17
PMID 26277114
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Little is known about the reliability of G8 screening tool and the prognostic value of clinical parameters within the Comprehensive Geriatric Assessment (CGA) in clinically fit older patients with hematological malignancies.

Materials And Methods: This study was performed to assess the reliability of G8 as a screening tool and to determine the predictive value of CGA items in terms of 1-year overall survival (OS). G8 and CGA were proposed to 107 consecutive patients (65-89 years) with hematological malignancies assessed by their physicians as clinically fit, meaning not exhibiting geriatric syndromes and/or irreversible comorbidities significantly impairing their daily function, and thus able to receive chemotherapy.

Results: Out of 107 patients, 90 patients were evaluable and completed both scales; 72% and 80% were defined as "vulnerable" when evaluated with G8 (≤ 14.5) or CGA (≥ 2 impairments) respectively. The area under ROC-curve of G8 compared to CGA was 0.749±0.051. Neither G8 nor CGA total scores were predictive of 1-year OS. However, age (HR=1.105, 95% CI: 1.016-1.202; p=0.019), diagnosis (HR=5.208, 95% CI: 1.895-14.310; p=0.001) and cognitive status (HR=3.260, 95% CI: 1.043-10.194; p=0.042) were predictive of OS.

Conclusions: We conclude that in our selected hematological patients: 1) the G8 score does not help selecting patients for CGA, 2) the G8 and CGA total scores do not predict OS, and 3) in addition to the age and disease itself, cognitive impairment appears to be a powerful prognostic factor.

Citing Articles

Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life.

Massaro F, Andreozzi F, Vandevoorde C, Bron D Cancers (Basel). 2023; 15(22).

PMID: 38001641 PMC: 10670135. DOI: 10.3390/cancers15225381.


Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults.

Huang L, Shi Y, Andreadis C, Logan A, Mannis G, Smith C J Geriatr Oncol. 2023; 14(8):101623.

PMID: 37678052 PMC: 11101048. DOI: 10.1016/j.jgo.2023.101623.


Remote assessment of cognitive dysfunction in hematologic malignancies using web-based neuropsychological testing.

Franco-Rocha O, Mahaffey M, Matsui W, Kesler S Cancer Med. 2022; 12(5):6068-6076.

PMID: 36221244 PMC: 10028155. DOI: 10.1002/cam4.5331.


The Impact of Cognitive Impairment on Treatment Toxicity, Treatment Completion, and Survival among Older Adults Receiving Chemotherapy: A Systematic Review.

Sattar S, Haase K, Tejero I, Bradley C, Mariano C, Kilgour H Cancers (Basel). 2022; 14(6).

PMID: 35326733 PMC: 8946153. DOI: 10.3390/cancers14061582.


Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.

Orellana-Noia V, Isaac K, Malecek M, Bartlett N, Voorhees T, Grover N Blood Adv. 2021; 5(18):3623-3632.

PMID: 34448831 PMC: 8945583. DOI: 10.1182/bloodadvances.2021004645.